UCLA faculty Michael Jung wearing a blue coat sitting in a room with blue lighting next to a desk fashioned with lab equipment.

#53

(2012) Breakthrough prostate cancer drug Xtandi, designed by a chemistry team led by UCLA faculty Michael Jung in collaboration with a team of biologists led by Dr. Charles Sawyers, is approved by the FDA. The royalty interest in Xtandi was sold for $1.14 billion in 2016, which has permitted scholarships, matching gift funds and support for research.